ASH HematOmics 计划:血液病基因组与临床数据整合分析平台
美国血液学会开发了 ASH HematOmics 计划(ASHOP),整合 5960 例血液肿瘤患者的基因组、转录组和临床数据,支持体细胞变异、基因融合、表达谱及临床结局的交互分析,并通过 4 个用例展示其应用价值。
要点
- ASHOP 整合 5960 例 B-ALL、T-ALL、AML、MDS 和 CLL 患者的基因组、转录组与临床数据。
- 平台支持自定义亚队列中显著突变基因分析、共突变模式可视化及转录组交互探索。
- 4 个用例验证了 ASHOP 在 DUX4 重排 B-ALL 分层、HOXA/HOXB 表达、MMR 缺陷和 TP53 变异分析中的实用性。
核心结论
- ASHOP 是一个开放获取的血液肿瘤基因组与转录组数据解读资源,可支持整合分析和临床队列精准定义。
研究设计与样本
- ASHOP 由美国血液学会开发,纳入 5960 例患者,覆盖 B-ALL、T-ALL、AML、MDS 和 CLL。
主要发现
- 平台提供体细胞变异、基因融合、转录组结果和临床数据的交互探索功能。
- 用户可分析自定义亚队列中的显著突变基因、共突变模式及差异表达和通路富集。
- 4 个用例展示了 DUX4 重排 B-ALL 的 Early/Multipotent 与 Committed 亚组具有不同结局。
关键数值与推荐
- ASHOP 覆盖 5960 例患者,包括 B 细胞前体和 T 细胞急性淋巴细胞白血病、急性髓系白血病、骨髓增生异常综合征和慢性淋巴细胞白血病。
临床怎么用
- 临床医生和研究者可通过 ASHOP 交互探索基因组变异景观、转录组特征及临床结局关联。
- 平台支持用户自定义亚队列以分析显著突变基因和共突变模式。
局限性
- ASHOP 目前覆盖的疾病类型和数据模态有限,计划未来扩展至更多疾病和数据类型。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The increasing availability of genomic and transcriptomic sequencing has uncovered diverse genomic alterations and distinct gene expression profiles driving hematologic diseases, yet a data integration and sharing platform dedicated to hematology remains lacking. We developed the American Society of Hematology (ASH) HematOmics Program (ASHOP; ashop.hematology.org), a resource for exploring somatic alterations and gene fusions, transcriptomic results, and clinical data from 5960 patients spanning B-cell precursor and T-cell acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndromes, and chronic lymphocytic leukemia. Users can explore genomic alteration landscapes and comutation patterns via lollipop and matrix plots and analyze significantly altered genes in user-defined subcohorts. Transcriptomes can be explored through interactive uniform manifold approximation and projections, clustering, differential expression, and pathway enrichment. Genomic, transcriptomic features, and clinical outcomes can be correlated in a user-driven manner or combined to precisely define study cohorts. We illustrate the following 4 use cases of ASHOP: (1) stratification of DUX4-rearranged B-cell leukemias into Early/Multipotent and Committed subgroups with distinct outcomes, (2) characterization of HOXA/HOXB expression patterns in acute myeloid leukemias, (3) correlating mutational burden with mismatch repair deficiency and mutational signatures, and (4) investigation of TP53 alteration landscape. ASHOP is an open-access resource to inform genomic and transcriptomic data interpretation for hematologic malignancies and will expand to support additional diseases and data modalities from the ASH community.
引用
- Lu C, Matt GY, Paul R, et al. The ASH HematOmics Program supports integrative analysis of genomic and clinical data in hematologic diseases. Blood. 2026. PMID: 41940951. doi:10.1182/blood.2025032031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。